Aaron M Drucker, MD, ScM, FRCPC, FAAD
Disclosures
Drucker reports no relevant financial disclosures.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.I'm always excited for new data on new treatments and old treatments. Anytime we get really excited about a new potential molecule that we see phase 1 and phase 2 data for, we need that big phase 3 data. So we've seen, presentations at the AAD and other conferences, for example, on anlotinib (Advenchen Laboratories, Jiangsu Chia-Tai Tianqing Pharmaceutical) , a new OX40 inhibitor, but I really wanna see those phase 3 publications out in print so I can fully evaluate that data and see what that might look like in closer proximity to clinical practice.
Also, you know, would love to see more comparative data comparing these treatments, comparing their efficacy in, you know, bigger randomized trials, and also comparing safety in observational studies where, you know, there are concerns, you know, particularly about JAK inhibitors, about long-term safety. We've seen a lot of reassuring data so far. I wanna see even more of that to help inform my clinical practice.
